Multiple polyadenylation sites in a large 3'-most exon of the rat insulin-like growth factor II gene

Hepatocellular carcinomas of the albumin SV40 T-antigen transgenic rat display fetal-like re-expression of lgf2 and deregulation of H19

Previous studies in our laboratory have shown that one of the earliest events during hepatocarcinogenesis in the albumin SV40 T antigen (Alb SV40 T Ag) transgenic rat is the duplication of chromosome 1q3.7-4.3, a region which contains the imprinted and coordinately regulated genes Igf2 and H19. We have also shown that this duplication is associated with the biallelic expression of the normally monoallelically-expressed H19. These results, however, are seemingly at odds with studies in the mouse that have shown a conservation of fetal regulatory patterns of these two genes in hepatic neoplasms. We therefore aimed in this study to determine the allelic origin of Igf2 expression in hepatocellular carcinomas of the Alb SV40 T Ag transgenic rat. Sprague-Dawley Alb SV40 T Ag transgenic rats and Brown Norway rats were reciprocally mated and the expression of Igf2 in hepatocellular carcinomas of the resulting F(1) transgene-positive female rats was analyzed by Northern blotting and RT-PCR. We determined that Igf2 was expressed exclusively from the paternal allele, which prompted the study (by the same methods) of the allelic origin of H19 in the same hepatocellular carcinomas in order to determine if the two genes remained coordinately regulated. Our results demonstrate fetal-like re-expression of Igf2 and deregulation of H19 in singular hepatocellular carcinomas of the rat. These results imply that another regulatory mechanism other than the generally accepted ICR/CTCF mechanism may play a role in the control of Igf2 and H19 expression.

Insulin-like growth factor II promoter expression in cultured rodent osteoblasts and adult rat bone

Insulin-like growth factor (IGF)-II stimulates bone formation by increasing the replication of cells of the osteoblastic lineage and by enhancing the differentiated function of the osteoblast. Although IGF-II is synthesized by skeletal cells, little is known about the mechanisms involved and its regulation by growth factors. IGF-II expression is tissue specific and is developmentally regulated. In the present study, we examined the expression of IGF-II in fetal rat, newborn mouse and MC3T3-E1 osteoblastic (Ob) cells, and in adult rat calvariae. We also determined mechanisms involved in the regulation of IGF-II by platelet-derived growth factor (PDGF) BB, fibroblast growth factor-2 (FGF-2), and transforming growth factor (TGF) beta1. Northern analysis revealed IGF-II transcripts of 3.6 and 1.2 kb in osteoblastic cells and adult rat calvariae. Ribonuclease (RNase) protection assay using probes specific to the three known IGF-II promoters, P1, P2, and P3, demonstrated messenger RNA (mRNA) expression driven by P3 in osteoblasts and adult rat calvariae, but no expression of P1 or P2 transcripts. PDGF BB, FGF-2, and TGF beta1 inhibited the expression of IGF-II P3 mRNA by 50%. PDGF BB, FGF-2, and TGF beta1 also decreased the rates of IGF-II transcription in rat Ob cells as determined by nuclear run-on assays and did not modify the decay of IGF-II in transcriptionally arrested rat Ob cells. In conclusion, the synthesis of IGF-II in osteoblastic cells and in adult rat calvariae is driven by IGF-II P3 and is regulated by skeletal growth factors acting at the transcriptional level using the IGF-II P3.

Insulinlike growth factor gene expression in rat muscle during reinnervation

Because insulinlike growth factors (IGFs) support motor axon regeneration, we tested whether the IGF genes expressed during the development of neuromuscular synapses are reexpressed in adult rat muscles during synapse regeneration. Following sciatic nerve crush, IGF-II mRNAs per poly(A)+ RNA, as well as per poly(A)+ RNA per milligram muscle, were significantly up-regulated in denervated relative to intact contralateral gastrocnemius muscles. IGF-II mRNAs were down-regulated after the reestablishment of functional neuromuscular synapses, but remained up-regulated when nerves were transected to prevent the reestablishment of synapses. These data are consistent with a model in which the IGF-II gene is reexpressed during regeneration due to loss of nerve-dependent feedback inhibition. There was a slight but significant increase in IGF-I mRNAs per poly(A)+ RNA per milligram muscle, probably as a consequence of muscle atrophy. These results show that IGF-II gene expression is up-regulated in muscle during the reestablishment of synapses.

Negative and positive regulation of IGF-II mRNA expression in cultured rat cells by chicken serum

We have investigated the possibility that some serum factors might negatively regulate the expression of the insulin-like growth factor-II (IGF-II) gene in 18-54, SF cells. Northern blot analyses indicated that there were three major transcripts (3.8 kb, 1.8 kb, and 1.2 kb) of the IGF-II gene in these cells. We found that incubation of 18-54, SF cells in medium containing very high concentrations (50-100%) of chicken serum greatly inhibited the steady-state level of all three IGF-II mRNA species. In addition, we also found that incubation of 18-54, SF cells in medium containing lower concentrations (10-50%) of chicken serum induced a 3.5 kb IGF-II mRNA. The inhibitory effect of high concentrations of chicken serum on IGF-II mRNA expression was not due to a cytotoxic effect of the serum, because these cells were maintained in 100% chicken serum for up to two weeks without loss of cell viability. The inhibitory effect of chicken serum on IGF-II mRNA was reversible after withdrawal of the serum. Nuclear run-on assays suggested that this negative regulation of IGF-II mRNA in 18-54, SF cells by chicken serum was not the result of transcriptional inhibition. Treatment of 18-54, SF cells that had been previously incubated in 100% chicken serum for 24 h with actinomycin D resulted in a partial restoration of the expression of the 3.8 kb and 1.2 kb IGF-II mRNA in these cells.(ABSTRACT TRUNCATED AT 250 WORDS)

Parental imprinting of an Igf-2 transgene

As a consequence of parental imprinting in mice, the paternal allele encoding insulin-like growth factor-II (IGF-II) is expressed, whereas the maternal allele is silent in most tissues. To examine whether cis-acting sequences involved in imprinting are located in the vicinity of the Igf-2 gene, we have constructed mouse transgenic lines and studied the expression of a 30 kb rat Igf-2 transgene, in which the coding region has been replaced with the lacZ reporter sequence. Chromatin position effects and/or absence of long-range regulatory elements seem to have affected tissue-specific expression in the transgenic mice. However, in one of six expressing lines, staining of embryos for beta-galactosidase activity was detected in a minor subset of tissues normally transcribing the endogenous homolog, but only when the transgene was transmitted paternally. This transgene was integrated into mouse chromosome 19, which is apparently free of imprinted loci. Although the possibility that the Igf-2 transgene was inserted into an as yet unidentified imprinted locus is discussed, a more likely interpretation of our results is that the transgene carries at least a portion of its own imprinting signal, because it consists of the genomic sequences of a locus already known to be imprinted and maintains the correct imprinting mode.

The effects of pituitary stalk transection, hypophysectomy and thyroid hormone status on insulin-like growth factor 2-, growth hormone releasing hormone-, and somatostatin mRNA prevalence in rat brain

We have used in situ hybridization histochemistry to determine the effects of pituitary stalk transection, hypophysectomy and drug-induced changes in thyroid status on mRNA levels encoding insulin-like growth factor 2, somatostatin, and growth hormone-releasing factor in the choroid plexus, hypothalamic periventricular nucleus, and arcuate nucleus, respectively. Pituitary stalk transection and hypophysectomy in Sprague-Dawley rats decreased insulin-like growth factor 2 and somatostatin mRNA and increased growth hormone-releasing factor mRNA. In each case, the effect of hypophysectomy exceeded that of pituitary stalk transection. Treatment with propylthiouracil for 10 days decreased somatostatin mRNA, markedly increased growth hormone-releasing factor mRNA but had no significant effect on insulin-like growth factor 2 mRNA. Treatment with triiodothyronine had no effect on the mRNAs measured. These findings corroborate the clinical observation of abnormal somatic growth in disturbances of thyroid and growth hormone status and provide further evidence of the effects of these metabolic disturbances and of pituitary disconnection and hypophysectomy on insulin-like growth factor 2 mRNA prevalence.

The molecular and cellular biology of insulin-like growth factor II

Insulin-like growth factor II (IGF-II) is a 67 amino acid polypeptide that belongs to the family of insulin-like peptides. The IGF-II gene is coupled to the insulin gene and paternally imprinted. Multiple IGF-II mRNAs with identical coding regions and 3' untranslated regions (UTRs) but different 5' UTRs are generated from 3 promoters. The transcripts are translationally discriminated and inactivated by a specific endonucleolytic cleavage in their 3' UTR. These features may be important in the control of IGF-II production. IGF-II functions in an auto- and paracrine manner and binds to two types of receptors. The IGF-I receptor that is a tyrosine kinase and closely related with the insulin receptor and the IGF-II/mannose 6-phosphate (IGF-II/Man 6-P) receptor that is identical with the cation-independent mannose 6-phosphate receptor. The mitogenic and metabolic actions of IGF-II are propagated by the IGF-I receptor. In contrast, the IGF-II/Man 6-P receptor, that target lysosomal enzymes from the Golgi apparatus or the plasma membrane to the lysosomes, mediates the rapid internalization and degradation of IGF-II. IGF-II is expressed at high levels during foetal life and it is a major growth factor for the foetus in rodents. The developmental profiles and tissue distribution of the IGF-I and the maternally imprinted IGF-II/Man 6-P receptors both parallel that of IGF-II. In this scenario IGF-II promotes the growth of the embryo through the IGF-I receptor, whereas the IGF-II/Man 6-P receptor balance the activity by controlling the extracellular level of IGF-II.

Developmental and tissue-specific regulation of ovine insulin-like growth factor II (IGF-II) mRNA expression

Insulin-like growth factor II (IGF-II) is believed to be involved in the development of the fetus. Northern and dot-blot analysis of RNA isolated from different sheep tissues at various stages of development were undertaken, revealing that the ovine IGF-II gene is expressed as a multitranscript family (6.0, 5.1, 5.0, 4.7, 3.8, 2.9, 2.3, 1.9, 1.6, 1.3 kb). Evidence that the ovine IGF-II gene may be regulated in a developmental, tissue-specific, co-ordinate or independent manner is presented. The developmental profile of IGF-II gene expression correlates with plasma levels (Mesiano et al. (1989) Endocrinology 124, 1485-1491), and suggests that the rapid fall in plasma concentration at term can be attributed to regulation at the transcriptional level. With the exception of the kidney, IGF-II expression was down-regulated at birth in all tissues examined. As in man but not rat, an adult liver-specific transcript was detected and attributed to different 5' untranslated regions in the fetal and adult IGF-II mRNAs. The finding of IGF-II transcripts in all tissues examined supports evidence from other species of autocrine/paracrine roles for IGF-II in the development of the fetus.

The presence and active transcription of three independent leader exons in the mouse insulin-like growth factor II gene

The presence of multiple leader exons is one of the common features in the insulin-like growth factor II (IGFII) genes. Among them the 5' most exon sequence, rE1, was so far reported to be present only in the rat genome. We have found a rE1-homologous sequence in the mouse genome (mE1) and have isolated it by genomic cloning. The mE1 sequence was located in the 5' region of the IGFII gene and was considered to take an integral part in the mouse IGFII gene construction, just like in the rat gene. Overall homology between mE1 and rE1 regions was approx. 95%. The mE1 was actively transcribed in the newborn tissues and generated approx. 3.8 kb RNA species. Since the other two leader exon sequences were also active, producing 4.6 kb and 3.6 kb RNA species, respectively, transcription units of the mouse IGFII gene were, thus, composed of three leader exon systems.

A bradykinin-like neuropeptide precursor gene is expressed in neuron L5 of Aplysia californica

Left upper quadrant (LUQ) cells in Aplysia californica extensively innervate the kidney and regulate some renal functions, although the nature of the neurotransmitters involved in these functions is still unknown. We isolated a new neuropeptide gene (LUQ-1) whose expression in the LUQ cells could be regulated posttranscriptionally by alternative choices of polyadenylation sites. This clone encodes a putative 16.3-kD precursor peptide which contains potential proteolytic cleavage sites that could generate smaller mature peptides. One of these peptides has a 63% identity with mammalian bradykinin/kallidin peptides. The Aplysia haploid genome contains a single copy of the gene, which is interrupted by at least one large intervening sequence. PCR assays performed with RNA isolated from individually dissected cells showed that the LUQ-1 gene is expressed only in neuron L5 among the LUQ cells.

Parental imprinting of the mouse insulin-like growth factor II gene

We are studying mice that carry a targeted disruption of the gene encoding insulin-like growth factor II (IGF-II). Transmission of this mutation through the male germline results in heterozygous progeny that are growth deficient. In contrast, when the disrupted gene is transmitted maternally, the heterozygous offspring are phenotypically normal. Therefore, the difference in growth phenotypes depends on the type of gamete contributing the mutated allele. Homozygous mutants are indistinguishable in appearance from growth-deficient heterozygous siblings. Nuclease protection and in situ hybridization analyses of the transcripts from the wild-type and mutated alleles indicate that only the paternal allele is expressed in embryos, while the maternal allele is silent. An exception is the choroid plexus and leptomeninges, where both alleles are transcriptionally active. These results demonstrate that IGF-II is indispensable for normal embryonic growth and that the IGF-II gene is subject to tissue-specific parental imprinting.

Structure, evolution, expression and regulation of insulin-like growth factors I and II

Insulin-like growth factors (IGF) I and II are chemically-related single-chain peptides with diverse actions on cellular growth and metabolism. This review will focus on recent information pertinent to the biochemical and molecular biological aspects of these peptides. Three areas will be examined: The structure of the two IGF molecules and their precursors will be analyzed; the complicated anatomy of the IGF genes and their mRNAs will be described; and the multiple ways in which the expression of IGF-I and IGF-II can be regulated will be discussed. Gaps in our understanding of these peptides will be highlighted in the context of opportunities for further investigation in this field.

Expression of insulin-like growth factor II (IGF-II) in human primary liver cancer: mRNA and protein analysis

Insulin-like growth factor II (IGF-II) is a polypeptide growth factor thought to be involved in fetal tissue development. We previously showed an increased expression of IGF-II mRNA in human primary liver cancer. The present investigation was undertaken to characterize the overexpressed IGF-II transcripts and to determine whether they are translated into protein. Two cDNAs with distinct 5' untranslated regions, corresponding to IGF-II transcripts expressed in fetal liver, were isolated from a primary liver cancer. Complete nucleotide sequence analysis showed an identical open reading frame of 540 bp, encoding a predicted polypeptide identical to the IGF-II isolated from serum. An increased synthesis of IGF-II protein was demonstrated by a protein-binding assay in tumorous liver samples, the highest levels being found in primary liver cancers with the highest IGF-II steady state level. By contrast, serum IGF-II content was low in most of primary liver cancer cases analyzed. Altogether, the results indicate reexpression of IGF-II both at the mRNA and protein levels in primary liver cancer. This finding is consistent with IGF-II being a marker of liver cell differentiation. In addition, this growth factor might be involved in liver cancer progression by an autocrine and/or paracrine mechanism.

Functional analysis of multiple promoters of the rat insulin-like factor II gene

We have characterized the multiple promoters of the rat insulin-like growth factor II (rIGFII) gene by in vivo transient expression assay using a series of deletion mutant templates. Among the four promoters (P1, P2, P3 and P6), two (P2 and P3) showed relatively strong promoter activities compared with the other two. One of the four promoters, P2, was further characterized by gel band-shift and footprinting analysis using HeLa cell nuclear extract, showing two retarded bands and at least one protected sequence stretch. The results indicated that P2 has a very simple structure like P3, and consists of no more than 141 base-pairs (bp) including a TATA box and two GC core hexanucleotides. Promoter strength shown by in vivo transient expression in different cell types failed to explain the differential employment of P2 and P3 in these cells, suggesting the involvement of other regulatory mechanisms that might operate only in the native state.